The Weill Cornell Breast Center has recently opened a new clinical trial for women with locally recurrent or metastatic breast cancer that was previously treated with anthracycline, a taxane, and capecitabine. The study sponsor is Nektar Therapeutics. The principal investigator at Weill Cornell is Dr. Tessa Cigler. For more information about the study, please call Marta Cobham, RN at (212) 821-0780 or e-mail Marta at email@example.com.
The purpose of the study is to test how well women with breast cancer respond to treatment with the experimental drug NKTR-102, compared to standard treatments for breast cancer. The study will also look at the side effects of the study drug and examine how long NKTR-102 stays in a patient’s blood.
Study participants will be randomly assigned to one of two study arms:
- Arm A: participants will receive NKTR-102 via infusion on Day 1 of each 21 day cycle.
- Arm B: participants will receive one of seven standard of care treatment options available at the study center. The choice of treatment in Arm B will be made after discussions with your doctor. Depending on which drug is chosen by you and your doctor, cycles in Arm B will be either 21 days or 28 days.
The study will take about 38 months to complete. The amount of time on study depends on how well a participant responds to study treatment.
- Women age 18 and older
- Diagnosed with breast cancer
- Locally recurrent or metastatic disease
- Prior therapy must have included anthracycline, a taxane, and Xeloda; must have received a minimum of 2 and maximum of 5 prior cytoxic chemotherapy regimens
- Detailed eligibility reviewed when you contact the study team